SARS-Cov-2
FDA authorizes ‘mix and match’ booster doses for COVID-19 vaccines
The FDA on Wednesday said it is OK for Americans to choose a different COVID-19 vaccine for their booster shot.
COVID-19 risk lower in US counties with robust primary care infrastructure
U.S. counties with the strongest primary care and public health infrastructures and social assets had the fewest SARS-COV-2 infections and related deaths, according to a report from the Primary Care Collaborative and Robert Graham Center.
Interferon adds no clinical benefit for hospitalized patients with COVID-19
Combining the immunomodulator interferon beta-1a with remdesivir did not improve treatment among hospitalized adults with COVID-19 compared with remdesivir alone, data from a clinical trial showed.
PPI use not linked to severe COVID-19 among US veterans
Proton pump inhibitors are not correlated with severe COVID-19 among U.S. veterans, according to results published in Gut.
FDA committee recommends second J&J shot at 2 months
An FDA advisory committee on Friday unanimously recommended that anyone who received the Johnson & Johnson COVID-19 vaccine should be able to receive a second dose at least 2 months after receiving their initial shot.
FDA advisory committee unanimously recommends Moderna booster shot
An FDA advisory committee on Thursday unanimously recommended the authorization of a booster dose of Moderna’s COVID-19 messenger RNA vaccine for certain people, to be given at half the regular dose.
More than half of COVID-19 survivors experience symptoms 6 months after recovery
More than half of COVID-19 survivors experience symptoms consistent with long COVID up to 6 months after recovery, data from a systematic review published in JAMA Network Open showed.
Patients with substance use disorder at higher risk for breakthrough SARS-CoV-2 infections
The risk for a breakthrough SARS-CoV-2 infection was significantly higher among patients with a substance use disorder than those without one, a population-based cohort study showed.
Regeneron cocktail reduces viral loads in hospitalized patients with COVID-19
The antibody cocktail of casirivimab and imdevimab significantly reduced viral loads in hospitalized patients with COVID-19 who were receiving low-flow or no supplemental oxygen, data presented at IDWeek showed.
AstraZeneca submits EUA request for COVID-19 prophylaxis
AstraZeneca this week submitted an emergency use authorization request to the FDA for AZD7442, a long-acting monoclonal antibody cocktail to be used for pre-exposure prophylaxis for symptomatic COVID-19 in adults.